About the Fleming Fund
The Fleming Fund is a UK aid programme to help low and middle income countries to fight antimicrobial resistance (AMR).
The Fleming Fund is named after Alexander Fleming who discovered the world's first antibiotic. Fleming's work paved the way for the use of antibiotics in modern healthcare.
When receiving the Nobel Prize in 1945 he warned of a time when antibiotics would become less useful due to frequent or improper use. Fleming, at this time, had predicted AMR.
AMR occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that make treatments ineffective. AMR causes drug resistant infections that can kill, spread to others and increase healthcare costs across the world.
AMR is a global issue. Read some important facts about AMR.
“Antimicrobial resistance has the potential to kill millions each year and become a massive burden on health systems across the world. By 2050, if left unchecked, drug-resistant infections will kill 10 million people a year and cost the worldwide economy $100 trillion. To combat this problem, we first need to understand it—and the Fleming Fund is a crucial step in creating a clearer global picture. Having accurate information will make sure the right resources are deployed at the right time, in the right place, to make the maximum impact.”
Chief Medical Officer Professor Dame Sally Davies
The aims of the Fleming Fund
The aim of the Fleming Fund is to get data relevant to AMR in the hands of decision makers.
We want to support countries generating the data they need to inform policies and practices which will optimise the use of antimicrobial medicines.
The Fleming Fund will fund a range of initiatives in low and middle income countries with the aim of increasing the quantity and quality of data available so we can better understand the scale and scope of AMR.
How will the Fleming Fund measure success?
The Fleming Fund will have supported over 30 countries in developing the tools and policies needed to tackle AMR, and will have established sustainable surveillance systems in 24 countries.
Success will be demonstrated by:
- an increase in the quantity and quality of available data relevant to AMR data
- an increase in data sharing nationally and across national borders
- evidence that the data has influenced positive changes in AMR related policies, practices and attitudes in order to optimise the use of antimicrobial medicines
The Fleming Fund includes an embedded independent evaluation to explore its impact and support adaptive management. The evaluation will explore:
- how much the quantity and/or quality of data on AMR at country level has increased, and to what extent the Fleming Fund has contributed to this increase
- to what extent the Fleming Fund's investments have been aligned with other relevant investments at country level
- how sustainable the country level data quantity and/or quality increase is likely to be
- whether improved AMR data has influenced (a) changes in national policies/regulations, and/or (b) changes in practice and attitudes in each country
- how much the quality of data shared and reported internationally has improved, and whether the Fleming Fund has contributed to this
- whether the Fleming Fund's investments at country level offer value for money
The evaluation will provide annual reports to the Fleming Fund to support continuous learning and adaption of the portfolio.